Comparative Pharmacology
Head-to-head clinical analysis: IOFLUPANE I 123 versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOFLUPANE I 123 versus SODIUM IODIDE I 123.
IOFLUPANE I-123 vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ioflupane I-123 is a radiopharmaceutical that binds with high affinity to the dopamine transporter (DAT) in the striatum. It allows visualization of presynaptic dopaminergic neurons via single-photon emission computed tomography (SPECT) imaging.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
Intravenous: 148-185 MBq (4-5 mCi) administered as a single IV bolus injection over 20-30 seconds, followed by saline flush.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
Clinical Note
moderateIoflupane I-123 + Methylphenidate
"Ioflupane I-123 may decrease effectiveness of Methylphenidate as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Venlafaxine
"Ioflupane I-123 may decrease effectiveness of Venlafaxine as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Nefazodone
"Ioflupane I-123 may decrease effectiveness of Nefazodone as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Fluvoxamine
Terminal elimination half-life of ioflupane I-123 is approximately 25-30 hours. This prolonged half-life allows for imaging up to 6-8 hours post-injection with sustained target-to-background ratio, but requires consideration for radiation safety.
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Primarily renal; about 60% of administered radioactivity excreted in urine within 24 hours, with 38% as unchanged ioflupane and 22% as metabolites. Fecal excretion accounts for approximately 14% over 48 hours. Additional elimination via biliary route is minimal.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical
"Ioflupane I-123 may decrease effectiveness of Fluvoxamine as a diagnostic agent."